Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma
NCT05256641Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), transformed lymphoma, secondary central nervous system lymphoma (SCNSL), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jan 2023; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)transformed lymphomasecondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT05256641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256641.